We are live on
!
Find out more
SGA
Sector Gamma AS Portfolio holdings
AUM
$423M
1-Year Est. Return
17.56%
This Fund
S&P 500
This Quarter
Est. Return
+14.33%
1 Year Est. Return
+17.56%
3 Year Est. Return
+28.73%
5 Year Est. Return
+52.48%
10 Year Est. Return
+238.19%
AUM
$439M
AUM Growth
+$35.4M
(+8.8%)
Cap. Flow
-$9.87M
Cap. Flow
% of AUM
-2.25%
Top 10 Holdings %
Top 10 Hldgs %
55.71%
Holding
44
New
3
Increased
22
Reduced
10
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$7.92M |
| 2 |
Elevance Health
ELV
|
+$7.75M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$5.12M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$4.87M |
| 5 |
Becton Dickinson
BDX
|
+$4.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$9.9M |
| 2 |
Baxter International
BAX
|
+$8.69M |
| 3 |
Viatris
VTRS
|
+$6.62M |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$6.47M |
| 5 |
Humana
HUM
|
+$6.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Regeneron Pharmaceuticals
REGN
$69.9B
| $5.53M | 1.26% |
+7,165
| New | +$4.87M |
|
|
27
Crinetics Pharmaceuticals
CRNX
$8.87B
| $5.35M | 1.22% |
+115,000
| New | +$5.12M |
|
28
Syndax Pharmaceuticals
SNDX
$1.82B
| $5.3M | 1.21% |
252,062
+41,248
| +20% | +$720K |
|
29
DexCom
DXCM
$28.3B
| $5.05M | 1.15% |
76,122
-699
| -0.9% | -$45.2K |
|
30
HCA Healthcare
HCA
$86.4B
| $5.03M | 1.15% |
10,784
-99
| -0.9% | -$46K |
|
31
Kura Oncology
KURA
$901M
| $4.74M | 1.08% |
455,841
+17,426
| +4% | +$183K |
|
32
PTC Therapeutics
PTCT
$6.29B
| $4.7M | 1.07% |
61,923
-56,189
| -48% | -$4.08M |
|
33
Ascendis Pharma A/S
ASND
$16.6B
| $3.48M | 0.79% |
16,305
-8,022
| -33% | -$1.66M |
|
34
CG Oncology
CGON
$6.48B
| $2.16M | 0.49% |
+52,039
| New | +$2.15M |
|
35
Organon & Co
OGN
$3.56B
| $2.15M | 0.49% |
300,000
-243,711
| -45% | -$1.93M |
|
36
Certara
CERT
$1.21B
| $2.03M | 0.46% |
230,565
| – | – |
|
|
ACLX
37
DELISTED
Arcellx
ACLX
| – | – |
-32,009
| Closed | -$2.63M |
|
|
38
Baxter International
BAX
$12.1B
| – | – |
-381,551
| Closed | -$8.69M |
|
39
BioNTech
BNTX
$23B
| – | – |
-27,732
| Closed | -$2.73M |
|
40
Elanco Animal Health
ELAN
$12.7B
| – | – |
-307,271
| Closed | -$6.19M |
|
|
41
Humana
HUM
$45.8B
| – | – |
-23,942
| Closed | -$6.23M |
|
42
Icon
ICLR
$13B
| – | – |
-24,967
| Closed | -$4.37M |
|
|
43
Viatris
VTRS
$20.5B
| – | – |
-668,851
| Closed | -$6.62M |
|
44
Solventum
SOLV
$13.9B
| – | – |
-59,259
| Closed | -$4.33M |
|
Similar funds
AFWM
MP
DS
RS
DF
OGM
CPIM
MPPLM
Sector Gamma AS's Q4 2025 Portfolio in Review
As of Q4 2025, Sector Gamma AS held 44 positions worth $439M, up 8.8% from $403M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Sector Gamma AS's Q4 2025 filing shows 3 new, 22 increased, 10 reduced and 8 closed positions. Its largest new stake was Crinetics Pharmaceuticals: 115,000 shares worth $5.35M. The largest sale was Pfizer, an estimated $9.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Sector Gamma AS's largest Q4 2025 buy was Crinetics Pharmaceuticals: 115,000 shares worth $5.35M.
- Sector Gamma AS added most to Bristol-Myers Squibb in Q4 2025, an estimated $7.92M increase.
- Sector Gamma AS's biggest Q4 2025 reduction was Pfizer, cutting an estimated $9.9M.
- Sector Gamma AS fully exited Baxter International in Q4 2025, selling an estimated $8.69M.
- Sector Gamma AS's ten largest holdings make up 56% of its $439M portfolio in Q4 2025.
- Sector Gamma AS opened 3 new positions and closed 8 in Q4 2025.
- Sector Gamma AS's portfolio value rose 8.8% quarter-over-quarter to $439M.
Based on Sector Gamma AS's 13F filing for Q4 2025, filed 12 Feb 2026.